These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 18512732

  • 1. Effects of Eg5 knockdown on human prostate cancer xenograft growth and chemosensitivity.
    Hayashi N, Koller E, Fazli L, Gleave ME.
    Prostate; 2008 Sep 01; 68(12):1283-95. PubMed ID: 18512732
    [Abstract] [Full Text] [Related]

  • 2. GLI2 knockdown using an antisense oligonucleotide induces apoptosis and chemosensitizes cells to paclitaxel in androgen-independent prostate cancer.
    Narita S, So A, Ettinger S, Hayashi N, Muramaki M, Fazli L, Kim Y, Gleave ME.
    Clin Cancer Res; 2008 Sep 15; 14(18):5769-77. PubMed ID: 18794086
    [Abstract] [Full Text] [Related]

  • 3. Use of a chemically modified antisense oligonucleotide library to identify and validate Eg5 (kinesin-like 1) as a target for antineoplastic drug development.
    Koller E, Propp S, Zhang H, Zhao C, Xiao X, Chang M, Hirsch SA, Shepard PJ, Koo S, Murphy C, Glazer RI, Dean NM.
    Cancer Res; 2006 Feb 15; 66(4):2059-66. PubMed ID: 16489005
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of an intratumoral controlled release formulation of clusterin antisense oligonucleotide complexed with chitosan containing paclitaxel or docetaxel in prostate cancer xenograft models.
    Springate CM, Jackson JK, Gleave ME, Burt HM.
    Cancer Chemother Pharmacol; 2005 Sep 15; 56(3):239-47. PubMed ID: 15864591
    [Abstract] [Full Text] [Related]

  • 5. Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms.
    Wang H, Yu D, Agrawal S, Zhang R.
    Prostate; 2003 Feb 15; 54(3):194-205. PubMed ID: 12518324
    [Abstract] [Full Text] [Related]

  • 6. Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer.
    Rocchi P, So A, Kojima S, Signaevsky M, Beraldi E, Fazli L, Hurtado-Coll A, Yamanaka K, Gleave M.
    Cancer Res; 2004 Sep 15; 64(18):6595-602. PubMed ID: 15374973
    [Abstract] [Full Text] [Related]

  • 7. Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide targeting Bcl-2 and Bcl-xL genes.
    Yamanaka K, Rocchi P, Miyake H, Fazli L, So A, Zangemeister-Wittke U, Gleave ME.
    BJU Int; 2006 Jun 15; 97(6):1300-8. PubMed ID: 16686729
    [Abstract] [Full Text] [Related]

  • 8. A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells.
    Yamanaka K, Rocchi P, Miyake H, Fazli L, Vessella B, Zangemeister-Wittke U, Gleave ME.
    Mol Cancer Ther; 2005 Nov 15; 4(11):1689-98. PubMed ID: 16275990
    [Abstract] [Full Text] [Related]

  • 9. Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin.
    Zellweger T, Miyake H, July LV, Akbari M, Kiyama S, Gleave ME.
    Neoplasia; 2001 Nov 15; 3(4):360-7. PubMed ID: 11571636
    [Abstract] [Full Text] [Related]

  • 10. Antisense oligonucleotide targeting of insulin-like growth factor-1 receptor (IGF-1R) in prostate cancer.
    Furukawa J, Wraight CJ, Freier SM, Peralta E, Atley LM, Monia BP, Gleave ME, Cox ME.
    Prostate; 2010 Feb 01; 70(2):206-18. PubMed ID: 19790231
    [Abstract] [Full Text] [Related]

  • 11. Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2'-O-(2-methoxy)ethyl chemistry.
    Zellweger T, Miyake H, Cooper S, Chi K, Conklin BS, Monia BP, Gleave ME.
    J Pharmacol Exp Ther; 2001 Sep 01; 298(3):934-40. PubMed ID: 11504787
    [Abstract] [Full Text] [Related]

  • 12. LG308, a Novel Synthetic Compound with Antimicrotubule Activity in Prostate Cancer Cells, Exerts Effective Antitumor Activity.
    Qin M, Peng S, Liu N, Hu M, He Y, Li G, Chen H, He Y, Chen A, Wang X, Liu M, Chen Y, Yi Z.
    J Pharmacol Exp Ther; 2015 Dec 01; 355(3):473-83. PubMed ID: 26377911
    [Abstract] [Full Text] [Related]

  • 13. Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models.
    Miyake H, Nelson C, Rennie PS, Gleave ME.
    Cancer Res; 2000 May 01; 60(9):2547-54. PubMed ID: 10811138
    [Abstract] [Full Text] [Related]

  • 14. Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis.
    Rocchi P, Beraldi E, Ettinger S, Fazli L, Vessella RL, Nelson C, Gleave M.
    Cancer Res; 2005 Dec 01; 65(23):11083-93. PubMed ID: 16322258
    [Abstract] [Full Text] [Related]

  • 15. Novel microtubule-targeting agents, pyrrolo-1,5-benzoxazepines, induce cell cycle arrest and apoptosis in prostate cancer cells.
    Nathwani SM, Cloonan SM, Stronach M, Campiani G, Lawler M, Williams DC, Zisterer DM.
    Oncol Rep; 2010 Dec 01; 24(6):1499-507. PubMed ID: 21042745
    [Abstract] [Full Text] [Related]

  • 16. A potent chemotherapeutic strategy in prostate cancer: S-(methoxytrityl)-L-cysteine, a novel Eg5 inhibitor.
    Xing ND, Ding ST, Saito R, Nishizawa K, Kobayashi T, Inoue T, Oishi S, Fujii N, Lv JJ, Ogawa O, Nishiyama H.
    Asian J Androl; 2011 Mar 01; 13(2):236-41. PubMed ID: 21297652
    [Abstract] [Full Text] [Related]

  • 17. A novel bis-indole destabilizes microtubules and displays potent in vitro and in vivo antitumor activity in prostate cancer.
    Ahn S, Hwang DJ, Barrett CM, Yang J, Duke CB, Miller DD, Dalton JT.
    Cancer Chemother Pharmacol; 2011 Feb 01; 67(2):293-304. PubMed ID: 20383708
    [Abstract] [Full Text] [Related]

  • 18. Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer.
    Gleave ME, Miyake H, Zellweger T, Chi K, July L, Nelson C, Rennie P.
    Urology; 2001 Aug 01; 58(2 Suppl 1):39-49. PubMed ID: 11502446
    [Abstract] [Full Text] [Related]

  • 19. Targeting prostate cancer with HTI-286, a synthetic analog of the marine sponge product hemiasterlin.
    Hadaschik BA, Ettinger S, Sowery RD, Zoubeidi A, Andersen RJ, Roberge M, Gleave ME.
    Int J Cancer; 2008 May 15; 122(10):2368-76. PubMed ID: 18240145
    [Abstract] [Full Text] [Related]

  • 20. 2-Methoxyestradiol and paclitaxel have similar effects on the cell cycle and induction of apoptosis in prostate cancer cells.
    Perez-Stable C.
    Cancer Lett; 2006 Jan 08; 231(1):49-64. PubMed ID: 16356831
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.